The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $9.87

Today's change-0.11 -1.10%
Updated July 1 11:03 AM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $9.87

Today's change-0.11 -1.10%
Updated July 1 11:03 AM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc down (U.S.)$0.11

Keryx Biopharmaceuticals Inc is lower today, dropping (U.S.)$0.11 or 1.10% to (U.S.)$9.87. Over the last five days, shares have lost 1.40% and are down 30.25% for the last year to date. This security has underperformed the S&P 500 by 43.48% during the last year.

Key company metrics

  • Open(U.S.) $10.05
  • Previous close(U.S.) $9.98
  • High(U.S.) $10.12
  • Low(U.S.) $9.74
  • Bid / Ask(U.S.) $9.87 / (U.S.) $9.88
  • YTD % change-30.25%
  • Volume769,922
  • Average volume (10-day)1,815,889
  • Average volume (1-month)1,428,246
  • Average volume (3-month)1,683,627
  • 52-week range(U.S.) $8.84 to (U.S.) $18.48
  • Beta3.24
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.34
Updated July 1 11:03 AM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-6,286.35%

Keryx Biopharmaceuticals Inc has a net profit margin of -6,286.35%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.44%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue1100
Total other revenue--------
Total revenue1100
Gross profit100--
Total cost of revenue100--
Total operating expense29403623
Selling / general / administrative19341612
Research & development1061910
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-28-40-35-23
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-28-40-35-22
Income after tax-28-40-35-22
Income tax, total0100
Net income-28-40-35-22
Total adjustments to net income--------
Net income before extra. items-28-40-35-22
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-28-40-35-22
Inc. avail. to common incl. extra. items-28-40-35-22
Diluted net income-28-40-35-22
Dilution adjustment------0
Diluted weighted average shares101929292
Diluted EPS excluding extraordinary itemsvalue per share-0.28-0.44-0.38-0.24
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.28-0.44-0.38-0.24